Embecta (NASDAQ:EMBC - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.20, Zacks reports. Embecta had a negative return on equity of 19.22% and a net margin of 5.25%. Embecta updated its FY 2025 guidance to 2.700-2.900 EPS.
Embecta Price Performance
Shares of Embecta stock traded up $0.08 during trading hours on Monday, hitting $17.50. 672,465 shares of the company's stock traded hands, compared to its average volume of 382,762. The company has a fifty day simple moving average of $19.58 and a 200-day simple moving average of $16.55. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of 17.50, a PEG ratio of 0.95 and a beta of 1.20. Embecta has a 12-month low of $9.93 and a 12-month high of $21.48.
Embecta Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 14th. Shareholders of record on Friday, February 28th will be given a $0.15 dividend. The ex-dividend date is Friday, February 28th. This represents a $0.60 annualized dividend and a yield of 3.43%. Embecta's dividend payout ratio is currently 60.00%.
Analyst Ratings Changes
EMBC has been the topic of a number of analyst reports. BTIG Research raised shares of Embecta from a "neutral" rating to a "buy" rating and set a $26.00 price objective on the stock in a research note on Wednesday, November 27th. Morgan Stanley upgraded Embecta from an "underweight" rating to an "equal weight" rating and lifted their price target for the company from $13.00 to $20.00 in a research note on Monday, December 2nd.
Read Our Latest Report on EMBC
Embecta Company Profile
(
Get Free Report)
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
See Also
Before you consider Embecta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.
While Embecta currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
